Nanosonics Limited · ASX:NAN
Nanosonics — ASX Spotlight Conference - London 2014
25 slides from Nanosonics's conference presentation, Mar 6, 2014
Slide 1: Leader in Infection Control Solutions
LEADER IN INFECTION CONTROL SOLUTIONS Addressing the need for safer, faster and eco-friendly high level disinfection of ultrasound probes Michael Kavanagh, CEO and President ASX Spotlight Conference - London March 6th 2014
Slide 2: Disclaimer
Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs o
Slide 3: Company Overview
Company Overview 150% NAN ASX300 Healthcare All Ords 140% Improving the safety of patients, clinics and their staff 130% 120% Proprietary automated system for low temperature, high level disinfection 110% ® 100% First product, trophon EPR for high 1/7/13 29/7/13 26/8/13 23/9/13 21/10/13 18/11/
Slide 4: Healthcare acquired infections (HAIs)
Healthcare acquired infections (HAIs) HAIs Diabetes Breast Cancer Heart Failure 73,249 98,987 Prostate Cancer 56,494 41,883 30,446 HAIs kill more people in the US each year than Breast Cancer and Prostate Cancer combined.1,2 Up to 70% of HAIs are preventable using existing infection prevention pra
Slide 5: Imaging procedure HAIs
Imaging procedure HAIs Imaging procedure HAIs – a critical subset of HAIs that are not often discussed. 0.9 - 9% of barrier sheaths and condoms leak.1, A meta-analysis has shown that 12.9% of transducers are contaminated with pathogenic bacteria following routine disinfection.2 HPV, a known ca
Slide 6: The need for disinfection in ultrasound
The need for disinfection in ultrasound Ultrasound transducers must be reprocessed between patients to prevent cross-infection. Any transducer that contacts broken skin, mucous membranes or sterile body cavities should be high level disinfected or sterlised.1 Heat sensitive transducer construc
Slide 7: Current HLD methods – time for change
Current HLD methods – time for change Disinfection processes unchanged in 20+ years Existing methods have many shortfalls The old methods: soak, spray or wipe • Chemical spills, vapour control present OH&S risks • High risk of cross contamination • Wipes and spray not approved by the FDA for HLD 7
Slide 8: Issues with current practice
Issues with current practice Efficacy: Pathogens have been found to remain on ultrasound transducers following disinfection with routine wipe and soaking methods.1-3 Inefficiency: Many disinfection methods cannot be performed at the bedside, meaning devices must be transported to a central steri
Slide 9: A new solution required …
A new solution required … The CEO of a group of imaging clinics in Canada captures the issue perfectly: “Here we are, with a new $150K ultrasound machine and $15K probes to go with it that we’re cleaning with 1960s glutaraldehyde soaking technology.” Feisal Keshavjee, CEO, Radiology Consultants Asso
Slide 10: trophon EPR
trophon® EPR First fully automated system for disinfection of ultrasound probes - compatible with all major ultrasound probes. offers a safer, quicker, quality assured method of disinfecting ultrasound intra-cavity probes 10
Slide 11: trophon EPR
trophon® EPR TRACEABLE > CS, - Meg, < nanoSonics ats ENTIR L a4
Slide 12: Our Technology – Nano-Nebulisation for Low Temperature Disinfection
Our Technology – Nano-Nebulisation for Low Temperature Disinfection High frequency sonic vibration turns disinfecting liquid into nano-sized droplets “Nano” droplets disperse like a gas − Covers entire surface of object being disinfected NanoNebulant is a strong oxidising agent − Lethal to bac
Slide 13: The case for trophon EPR - efficacy
The case for trophon EPR - efficacy A peer-reviewed publication reported on 59 different efficacy experiments at four different testing locations in Europe and Australia. Successful tests against 21 species of bacteria, fungi and viruses demonstrated the HLD efficacy of trophon EPR using multiple
Slide 14: Attractive Revenue Model
Attractive Revenue Model Multiple revenue streams: Up-front sales plus consumables, accessories and service contracts Accessories Trophon Consumables Service & maintenance contracts 35% 5% 45% 15% Figures refer to % of revenue Each unit sale results in robust annuity type revenue streams moving forw
Slide 15: Nanosonics: Financial Results for H1 F14
Nanosonics: Financial Results for H1 F14 H1 F14 H1 F13 % Change $million $million USA 7.994 3.034 163% Aus/NZ* 1.094 1.213 10% Europe +ROW .592 .173 242% Total Sales Revenue 9.68 4.42 119% Operating Expenses 10.3 9.4 10% Operating Loss 3.482 6.027 42% * Due to order timing Sales $'m H1 H2 SALES REVE
Slide 16: North America
North America 16
Slide 17: 38 of the top 50 Hospitals as of Jan 2014
38 of the top 50 Hospitals as of Jan 2014
Slide 18: 1286 USA locations as of Jan 2014
1286 USA locations as of Jan 2014 locations may have multiple units installed
Slide 19: United Kingdom
United Kingdom • Number of key hospitals adopting trophon EPR • Health Boards reviews nearing completion • Awareness activities progressing 19
Slide 20: Medicines & Healthcare products Regulatory Agency
Medicines & Healthcare products Regulatory Agency Government agency with responsibilities for standards of safety, quality & performance Medical Device Alert Ref: MDA/2012/037 Issued: 28 June 2012 Device Problem Action • Reusable transoesophageal, echocardiography, • The MHRA is aware of an incident
Slide 21: Health Boards review nearing completion
Health Boards review nearing completion News Ultrasound Probe Decontamination - National Survey Launched Full review of TV and TR reprocessing services in order to establish clear 4th October 2012 National Recommendations underway In August HFS launched a national survey of current decontamination p
Slide 22: Recent market survey
Recent market survey Survey conducted amongst 70 Superintendent Sonographers: 120% Are you aware of the need to High 100% Level Disinfect TV and TR probes? 80% 60% Were you aware of this need 1 year 40% ago? 20% 0% Customer Awareness Oct Customer Awareness Oct 2012 2013 Are you actively looking at s
Slide 23: Whittington Hospital
Whittington Hospital In light of the serious cost pressures facing UK NHS Trust Hospitals there is a recognition of the potential issues which may result from inappropriate U/S probe care Trophon approved by Whittington Hospital
Slide 24: Summary
Summary Fundamentals for the business continue to strengthen Growing awareness of the Healthcare Acquired Infection risk associated with Imaging Regulation / Guidelines – Trends towards stricter controls (HLD) and Automation. Risk mitigation growing in importance under Accountable Healthcare m
Slide 25: Thank You
THANK YOU